The Relationship Between Health-Related Quality of Life and Anabolic Hormone Levels in Middle-Aged and Elderly Men With Prediabetes: A Cross-Sectional Study

Michał Rabijewski, PhD, Lucyna Papierska, PhD, Radosław Maksym, PhD, Ryszard Tomasiuk, PhD, Anna Kajdy, PhD, and Bogusław Paweł Siekierski, PhD

Abstract
The aim of this study was to compare health-related quality of life (HRQoL) between men with prediabetes (PD) and a control group as well as to investigate the relationship between HRQoL and anabolic hormones. The analysis was carried out in 176 middle-aged (40–59 years) and elderly (60–80 years) men with PD, and 184 control peers. PD was defined according to the American Diabetes Association and HRQoL was assessed by the SF-36 questionnaire. Total testosterone (TT), calculated free testosterone, dehydroepiandrosterone sulfate (DHEAS), and insulin-like growth factor 1 (IGF-1) were measured. Analysis of the standardized physical and mental component summary scores (SF-36p and SF-36m) revealed that patients with PD had lower SF-36p and SF-36m than control group (p < .02 and p < .001). Middle-aged men with PD had lower SF-36p and SF-36m than control peers, whereas elderly men with PD had lower only SF-36p. In men with PD negative correlations between glycated hemoglobin (HbA1c) and SF-36m score (r = −0.3768; p = .02) and between HbA1c and SF-36p score (r = −0.3453; p = .01) were reported. In middle-aged prediabetic men, SF-36p was associated with high free testosterone and low HbA1c while SF-36m with high TT and high DHEAS. In elderly patients with PD, SF-36p was associated with high TT, high IGF-1, and low HbA1c, while SF-36m correlated with high free testosterone and high DHEAS. In conclusion, PD in men is associated with decreased HRQoL in comparison with healthy men, and generally better quality of life is associated with higher testosterone, higher free testosterone, higher DHEAS, and lower HbA1c.

Keywords
prediabetes, quality of life, anabolic hormones, men

Received February 7, 2018; revised April 20, 2018; accepted April 24, 2018
The relationship between HRQoL and anabolic hormones levels can be of potential importance because both conditions affect aging men and the management of one may have a positive effect on the other. A few studies have attempted to demonstrate the presence of a relationship between sex hormones, sexual dysfunctions, and PD (Corona et al., 2012; Ho et al., 2013) but to the best of our knowledge it is as yet unknown whether there exists any association between HRQoL and anabolic hormones in the specific case of prediabetic men.

This study compared HRQoL, as assessed by the SF-36 questionnaire, between patients with PD and a suitable control group, and also investigated the relationship between HRQoL and anabolic hormones levels in middle-aged and elderly men with PD.

**Material and Methods**

The study was conducted in the Department of Internal Diseases, Diabetology and Endocrinology, Medical University of Warsaw, Poland, in patients who presented at the outpatient clinic for management of glucose metabolism disorders. The inclusion criteria were as follows: (a) a laboratory proved PD, (b) age 40–80 years, (c) steady sexual relationship for the last 6 months, and (d) no prior history of depression. The exclusion criteria were defined as follows: (a) diabetes mellitus type 1 or 2; (b) conditions that affect sexual function such as history of transurethral resection of prostate, hyperprolactinemia, thyroid function disorders, and neurological diseases; (c) recent or current testosterone replacement, androgen deprivation therapy, or any other hormonal treatment either during the study or in prior history; and (d) lack of informed written consent. The analysis was carried out in 176 consecutive patients with PD (aged between 40 and 80 years), and in 184 men without glucose metabolism disorders matched by age, with fasting plasma glucose (FPG) less than 5.55 mmol/L (100 mg/dl), and HbA1c less than 5.7%. Study groups were divided by age: middle-aged men—from 40 to 59 years old, and elderly men—from 60 to 80 years old. This study was conducted in accordance with the Declaration of Helsinki.

PD was diagnosed in the patients with IGF from 100 to 125 mg/dl (5.6–6.9 mmol/L) and two-hours glucose concentration in oral glucose tolerance test (OGTT) <140 mg/dl (<7 mmol/L); the same was also used in diagnosis of patients with IGT - 2-hour glucose concentration in OGTT that ranged from 140 to 200 mg/dl (7.8–11.0 mmol/L) or in patients who presented with HbA1c ranging from 5.7% to 6.4% (American Diabetes Association, 2014). Because PD is a transitory state with many individuals exhibiting blood glucose levels within the normal range upon repeated testing, FPG and OGTT measurements were analyzed again after 2–3 weeks and...
reevaluated accordingly. PD was confirmed in 95% of men in repeated analysis, and only men with twice proved PD were included in this study. The diagnosis of metabolic syndrome (MetS) was based on the presence of a waist circumference of ≥94 cm and any two of the following criteria: triglycerides ≥150 mg/dl, HDL-cholesterol <40 mg/dl, blood pressure ≥130/85 mmHg, and FPG ≥100 mg/dl (Athyros, Gionanakis, & Mikhailidis, 2005). Height and weight were measured for all subjects and body mass index (BMI) was calculated. Obesity was defined as a BMI of 30 or more. CVD was defined as coronary artery disease, congestive heart failure, or arrhythmia. Hypertension and chronic obstructive pulmonary disease (COPD) were considered to be present if a participant reported having received the diagnosis or if he was receiving medication for the same. The prevalence of CVD, MetS, obesity and hypertension was similar in men with PD and in control group.

**Assessment of health-related quality of life (HRQoL).** The SF-36 (Ware et al., 1993) is a widely used and much validated instrument for the assessment of HRQoL (Haywood, Garratt, & Fitzpatrick, 2005); it measures the health status of the individual and comprises 36 items related to eight dimensions: physical functioning for the limitation in performing all physical activities, role-physical for problems with work or other daily activities, bodily pain, general health, vitality, social functioning, role-emotional, and mental health (Ware et al., 1993). The dimensions such as physical functioning, role-physical, bodily pain, and general health reflect the physical component of health whereas the dimensions vitality, social functioning, role-emotional, and mental health reflect the mental components of health. In detail, physical functioning refers to the ability of the individual to perform activities (walking, climbing stairs, bending and stretching, lifting and carrying objects) without limitation, whereas role-physical refers to the limitations that the reduced physical health imposes on the range and extent of physical activities that one is able to perform. Bodily pain refers to the severity of pain and its impact on daily activities while general health is a rating of one’s own health in a comparison to the health of others and susceptibility to illness. Social functioning refers to the impact of physical and emotional health on the ability to perform normal social activities and vitality refers to exuberant mental vigor. Role-emotional refers to limitations that emotional problems place upon the range and extent of activities one is able perform and mental health refers to the degree of nervousness, calm, happiness, or sadness. We calculated the raw scores of the SF-36 separately for all eight dimensions and also we calculated physical and mental component summary scores (SF-36p, SF-36 physical component summary score; SF-36m, SF-36 mental component summary score) such that each ranges between 0 to 100. Higher scores on the SF-36 indicate a higher HRQoL.

**Laboratory measurements.** For all study subjects, venous blood samples were obtained between 8.00 and 10.00 a.m. After centrifugation, the serum was collected and frozen at −70 °C until required for analysis purposes. FPG was measured with the enzymatic method using the BIOSEN 5040 analyzer (EKF-Diagnostic GmbH, Germany), and HbA1c was measured with the HPLC method using a variant analyzer (Bio-Rad Laboratories Inc, USA). HbA1c values were expressed as percentage in accordance with the National Glycohemoglobin Standardization Program (NGSP). Serum levels of total testosterone (TT), DHEAS, estradiol (E2), and IGF-1 were measured with immunometric assays (Immulite 2000 and RIA CAC; Siemens Medical Solution, Malvern, PA, USA) and expressed in nmol/L for TT, pg/ml for E2, and ng/ml for DHEAS and IGF-1 (to convert the values obtained for DHEAS into nmol/L, simply multiply by 0.00271; IGF-1 to nmol/L, multiply by 0.131; and E2 to pmol/L, multiply by 3.671). To estimate the circulating fraction of free testosterone (FT), the serum level of sex hormone-binding globulin (SHBG) was measured using an immunoassay (Diagnostic Products Corp, San Francisco, CA), and SHBG was expressed in nmol/L. The serum level of calculated free testosterone (cFT) was expressed in nmol/L, and calculated with the validated equation of Vermeulen et al. (Vermeulen, Verdonck, & Kaufman, 1999), according to the following formula: cFT = T – N – S + √((N + S – T)² + 4NT))/2N, where T, S, and A are TT (nmol/L), SHBG (nmol/L) and albumin (g/L) concentrations; N = 0.5217A + 1, using the association constants of testosterone for SHBG (109 L/mol) and albumin (3.6 104 L/mol) quoted by the authors. TT levels < 12 nmol/L and cFT levels < 0.250 nmol/L were taken as low.

**Statistical analysis.** Statistical analyses were performed using the Statistica 9.1 data analysis software system (StatSoft, Tulsa, OK, USA). Most continuous variables were observed to have a normal distribution and were expressed as mean ± standard deviation. The intergroup differences were tested using t-test for unpaired samples. Serum DHEAS had a skewed distribution so the results were log-transformed so as to normalize distribution and expressed as a median with lower and upper quartiles; the intergroup differences were tested using t-test for unpaired samples for normalized values. Categorized variables were expressed as numbers and percentages, and the intergroup differences were tested using χ² test.

The relationships between SF-36 scores and various factors including age, BMI, and HbA1c in men with PD
were examined by the Pearson’s correlation analyses (separately for SF-36 p and SF-36 m summary scores). Univariable and multivariable linear regression analyses were applied to establish variables determining HRQoL as assessed by the SF-36. Regression analyses were performed separately in the younger (40–59 years) and older (60–80 years) age groups. In the univariable analyses, as the potential determinants of the severity of the eight SF-36 dimensions (separately for SF-36 p and SF-36 m summary scores), we included: age, BMI, HbA1c, TT, cFT, DHEAS, and IGF-1 as well as comorbidities such as CVD, obesity, and MetS. During the construction of the multivariable models, all variables that have been shown to be significant \((p < .05)\) determinants in the univariable analyses were included. A \(p\) value less than .05 was considered statistically significant.

### Results

A total of 176 men with PD, mean age 59 ± 6 years (102 men 40–59 years, and 74 men 60–80 years old), and 184 healthy men, mean age 61±5 years (98 men from 40 to 59 years and 86 men from 60 to 80 years old), were evaluated in this study. Patients with PD had lower TT and cFT levels than observed for the control group \((p < .02\) and \(p < .05\), respectively), while DHEAS, IGF-1, and SHBG levels were not observed to differ significantly. Results also showed higher estradiol levels and BMI in men with PD \((p < .02\) and \(p < .05\), respectively). HbA1c and total cholesterol were significantly higher in prediabetic men \((p < .001\) and \(p < .05\), respectively) as were the prevalence of obesity and MetS (see Table 1).

| Clinical and laboratory variables | PD 40–80 years, \(n = 176\) | PD 40–59 years, \(n = 102\) | PD 60–80 years, \(n = 74\) | Control group, \(n = 184\) |
|---------------------------------|-------------------------------|-----------------------------|-----------------------------|-----------------------------|
| **Age, y**                      | 59 ± 6                        | 52 ± 4                      | 68 ± 5                      | 61 ± 5                      |
| **TT, nmol/L**                  | 13.5 ± 3.9                    | 15.9 ± 3.5                  | 11.6 ± 3.7                  | NS                          |
| **cFT, nmol/L**                 | 0.326 ± 0.08                  | 0.359 ± 0.09                | 0.313 ± 0.08                | .001                        |
| **DHEAS, ng/ml**                | 541 (196–884)                 | 675 (229–921)               | 238 (159–739)               | .01 698 (234–967)            |
| **IGF-1, ng/ml**                | 89.5 ± 46.3                   | 94.6 ± 47.6                 | 88.5 ± 41.5                 | NS                          |
| **LH, IU/L**                    | 5.8 ± 1.4                     | 5.4 ± 1.4                   | 6.2 ± 1.5                   | .05 5.1 ± 1.3               |
| **E2, pg/ml**                   | 29.7 ± 9.2                    | 28.2 ± 12.5                 | 32.9 ± 10.7c                | .02 26.9 ± 11.7              |
| **SHBG, nmol/L**                | 32.6 ± 4.2                    | 31.4 ± 4.1                  | 32.9 ± 3.8                  | NS 30.7 ± 5.1               |
| **BMI, kg/m²**                  | 29.3 ± 4.4                    | 28.7 ± 4.5                  | 30.5 ± 4.6                  | .05 27.5 ± 4.2              |
| **HbA1c, %**                    | 6.0 ± 0.3                     | 5.8 ± 0.2                   | 6.1 ± 0.3                   | .02 5.4 ± 0.2               |
| **FPG, mg/dl**                  | 115 ± 5.9                     | 113 ± 5.2                   | 122 ± 6.4                   | .01 88 ± 7.8               |
| **Glucose in OGTT, mg/dl**      | 140 ± 6.3                     | 138 ± 12.3                  | 146 ± 12.1                  | .05 128 ± 13               |
| **Cholesterol, mg/dl**          | 221 ± 42                      | 219 ± 43                    | 226 ± 38                    | .05 209 ± 14               |
| **Triglycerides, mg/dl**        | 168 ± 13                      | 166 ± 14                    | 173 ± 14                    | NS 163 ± 15               |
| **HDL-cholesterol, mg/dl**      | 36 ± 5                        | 38 ± 6                      | 34 ± 5                      | .05 39 ± 7                |
| **LDL-cholesterol, mg/dl**      | 148 ± 23                      | 144 ± 23                    | 152 ± 24                    | NS 141 ± 21               |
| **Obesity, %; (no.)**           | 68 (120)                      | 71 (72)                     | 65 (43)                     | NS 60 (111)               |
| **Hypertension, %; (no.)**      | 51 (82)                       | 37 (39)                     | 58 (43)                     | .01 48 (88)               |
| **MetS, %; (no.)**              | 80 (142)                      | 79 (81)                     | 84 (62)                     | NS 61 (112)               |
| **CVD, %; (no.)**               | 18 (32)                       | 10 (10)                     | 30 (22)                     | .001 16 (29)              |
| **COPD, %; (no.)**              | 17 (30)                       | 13 (13)                     | 23 (17)                     | .05 14 (25)              |

Note. Data are presented as a mean ± standard deviation of the mean, a median (with lower and upper quartiles), or number (percentage), where appropriate. BMI = body mass index; TT = total testosterone; cFT = calculated free testosterone; LH = luteinizing hormone; PD = prediabetes; DHEAS = dehydroepiandrosterone sulfate; SHBG = sex hormone binding globuline; E2 = estradiol; HbA1c = glycated hemoglobin; IGF-1 = insulin-like growth factor 1; FPG = fasting plasma glucose; OGTT = oral glucose tolerance test; MetS = metabolic syndrome; CVD = cardiovascular disease; COPD = chronic obstructive pulmonary disease. *Differences between prediabetic men 60–80 years and 40–59 years old. **Difference between all patients with PD and control group.
Table 2. Means of the Scales in the SF-36 Between All Patients With PD, in the Two Age Group Patients With PD, and In Control Group.

| SF-36 dimensions                | PD 40–80 years, n = 176 | PD 40–59 years, n = 102 | PD 60–80 years, n = 74 | Control group, n = 184 | p*  | p** |
|--------------------------------|-------------------------|-------------------------|------------------------|------------------------|-----|-----|
| Mental health component        |                         |                         |                        |                        |     |     |
| Mental health                  | 84 ± 11.4               | 87 ± 14.5               | 83 ± 13.4              | .01                    | 88 ± 15.5       | .05 |
| Social functioning             | 78 ± 12.2               | 79 ± 13.4               | 77 ± 17.8              | NS                     | 81 ± 17.5       | NS  |
| Role-emotional                 | 80 ± 14.7               | 81 ± 12.5               | 79 ± 16.3              | NS                     | 81 ± 15.8       | NS  |
| Vitality                       | 75 ± 17.5               | 78 ± 12.5               | 71 ± 15.7              | .01                    | 82 ± 14.8       | .02 |
| Physical health component      |                         |                         |                        |                        |     |     |
| General health                 | 74 ± 14.2               | 78 ± 12.6               | 69 ± 14.6              | .01                    | 82 ± 12.8       | .02 |
| Bodily pain                    | 80 ± 12.5               | 83 ± 11.8               | 81 ± 12.2              | NS                     | 82 ± 12.4       | NS  |
| Physical functioning           | 82 ± 11.1               | 83 ± 12.5               | 82 ± 11.8              | NS                     | 82 ± 12.7       | NS  |
| Role-physical                  | 77 ± 13.3               | 78 ± 11.4               | 76 ± 12.3              | NS                     | 78 ± 10.2       | NS  |

Note. Data are presented as a mean ± standard deviation of the mean; SF-36 dimension scores range from 0 to 100, where a higher score reflects better functioning. PD = prediabetes.

* Differences between prediabetic men 60–80 years and 40–59 years old. ** Differences between all patients with PD and control group.

The independent t-test was used to analyze the unadjusted means of the scores for the eight dimensions in the SF-36 form for all study subjects, PD as well as the control group (Table 2). Results revealed that the mean scores for mental health, vitality, and general health were statistically significantly lower in patients with PD (p < .05, p < .02, and p < .02, respectively). Differences in other SF-36 dimensions were not significant between the prediabetic subjects and the control group. An analysis of both groups with respect to age revealed that the means of scores for mental health and general health dimensions in the SF-36 in case of middle-aged men with PD were significantly lower than that for the healthy peers (p < .02 and p < .05, respectively; Figure 1A). Similarly, in elderly men with PD, the means for vitality, mental health, and physical functioning were significantly lower than those computed for the healthy peers (p < .02, p < .01, and p < .05; respectively; Figure 1B). An analysis among patients with PD revealed that the mean scores for mental health, vitality, general health, and physical functioning, as per SF-36, were significantly higher in middle-aged subjects than that seen for elderly prediabetic men (p < .02, p < .01, p < .05, and p < .02, respectively; Table 2).

The statistical analysis of the standardized physical and mental component summary scores (SF-36p, and SF-36m) revealed that patients with PD had lower SF-36p (79 ± 13.5 vs. 81 ± 13.9; p < .02) and SF-36mp scores (80 ± 14.2 vs. 83 ± 14.3; p < .001) than control group. Analysis of both groups after dividing by the age revealed that middle-aged men with PD had the lower than control group both SF-36p (80 ± 14.2 vs. 83 ± 13.4; p < .02), and SF-36mp (81 ± 13.4 vs. 86 ± 14.5; p < .001), while elderly men with PD had the lower SF-36 than control group (77 ± 15.6 vs. 81 ± 16.5; p < .01) but differences of SF-36mp did not differ significantly between groups (78 ± 13.3 vs. 79 ± 14.5; NS). Among patients with PD, middle-aged patients were observed to have higher SF-36p scores (p < .02) whereas the SF-36mp score did not differ significantly when the same was compared for middle-aged and elderly prediabetic men.

The perceived relationship between SF-36 scores and age, and, BMI and HbA1c in men with PD was examined by Pearson’s correlation analyses (separately for SF-36p and SF-36mp summary scores). Significant negative correlations were observed between HbA1c and SF-35mp (r = −0.3768; p = .02) and between HbA1c and SF-36mp (r = −0.3453; p = .01). No other additional correlations of significance were noticed between the analyzed variables including age.

In middle-aged men with PD in multivariable linear regression models, SF-36p score was independently associated with high cFT, low HbA1c, and the absence of obesity (all p < .05), whereas the SF-36mp score was independently associated with high TT and DHEAS levels, and the lack of MetS (all p < .05). For elderly patients with PD, using the same statistical multivariable linear regression model, it was seen that the SF-36p score was independently associated with high TT and IGF-1, low HbA1c, and the lack of obesity (all p < .05) while SF-36mp scores were independently associated with high cFT and DHEAS levels, and the lack of obesity (all p < .05; Table 3).

Discussion

Currently available literature has consistently reported that T2DM is associated with poorer HRQoL; however, to the best of our knowledge, information regarding the scale of this phenomenon in patients with PD is limiting. In particular, the relationship between HRQoL and anabolic
hormone levels in men with PD remains poorly understood. This kind of analysis seems particularly relevant seeing as how increased life expectancy has led to an increase in the incidence of age-related PD and anabolic hormones deficiencies. In light of the above mentioned data, HRQoL as assessed by the SF-36 questionnaire in men with PD as well as in a suitable control group was evaluated; investigations were also undertaken for probing the relationship between HRQoL and anabolic hormones levels in middle-aged and elderly men with PD.

The results of the study can be summarized in four major findings. First, an in-depth analysis of the results strongly proved that the mean scores for mental health, vitality, and general health were significantly lower in patients with PD than the control group. The analysis of both groups conducted after separating them on the basis of age revealed that the mean scores for mental health and general health in middle-aged men with PD were significantly lower than that observed for their healthy peers; while in elderly men with PD, the means for

Figure 1. Analysis of the unadjusted means of the scores of eight dimensions in the SF-36 between middle-aged men (40–59 years) with PD and healthy peers (A) and between elderly men (60–80 years) with PD and healthy peers (B). SF-36m and SF-36p scores range from 0 to 100, where a higher score reflects better functioning. MH = mental health; SF = social functioning; RE = role-emotional; V = vitality; GH = general health; BP = bodily pain; PF = physical functioning; RP = role-physical.
vitality, mental health, and physical functioning were significantly lower as compared to healthy peers. It was also identified that among the patients with PD, the mean scores for mental health, vitality, general health, and physical functioning were significantly higher in case of middle-aged men with PD. The analysis of the summary scores revealed lower SF-36p and SF-36m scores in men with PD than in the control group; middle-aged men with PD had lower SF-36p and SF-36m than their healthy peers while elderly men with PD were observed to present only with lower SF-36p values. Among patients with PD, the middle-aged group presented with higher SF-36p scores but the SF-36m score did not appear to differ significantly. Based on the obtained results, it seems that PD can negatively impact the HRQoL in men but the impact varies depending on the age of patients.

The second noteworthy observation was as follows: relationships between SF-36m and SF-36p in patients with PD, as examined by Pearson’s correlation analyses, were independent of age and BMI. However, negative correlations were observed between HbA1c and SF-35m as well as SF-36p scores. These results also allow to hypothesize that even a small degree of imbalance in glucose metabolism can result in poorer HRQoL in men.

Third, data obtained through multivariable linear regression analysis forward the supposition that hormonal and clinical determinants of HRQoL were different in middle-aged and elderly men with PD. In middle-aged men with PD, SF-36p was associated with high cFT, low HbA1c, and the lack of obesity while SF-36m was associated with high TT, high DHEAS, and the lack of obesity. Generally, it can be concluded that better HRQoL in men with PD is associated with higher anabolic hormones and lower HbA1c.

The last noteworthy observation was that men with PD had lower TT and cFT levels than the control group, whereas levels of DHEAS and IGF-1 did not appear to differ significantly. Also, elderly patients with PD had lower TT, cFT, and DHEAS than middle-aged men.

Knowledge about associations between sex hormones and glucose metabolism disorders, especially PD, is limited. In this study, the lower TT and cFT levels in men with PD when compared with control men were reported, but the exact pathophysiological relationships are not yet clearly explained. Cross-sectional studies report that 30%–50% of men with T2DM have lowered TT levels (Dhindsa et al., 2004; Kapoor et al., 2007). This association persists if adjusted for confounders including age and obesity, and it is estimated that T2DM is associated with reduction in TT in magnitude comparable with the effect of 10 years of aging. Diabetic men with low TT are significantly more likely to be obese and insulin resistant (Schianca et al., 2017) and have increased mortality. Low TT levels are associated with insulin resistance (Grossmann, 2014) because testosterone promotes the commitment of pluripotent stem cells into the myogenic lineage and inhibits their differentiation into adipocytes (Singh, Artaza, Taylor, Gonzalez-Cadavid, & Bhasin, 2003), and these changes are expected to be metabolically favorable. In addition, testosterone regulates the metabolic functions of mature adipocytes and myocytes in ways that reduce insulin resistance (Grossmann, 2014).

There is also evidence for reverse causality, demonstrating that low testosterone may be a consequence of

| Table 3. Parameters Significantly Associated With the Standardized Physical (SF-36p) and Mental (SF-36m) Component Summary Scores in Men (n = 176) With PD. |
|---------------------------------------------------------------|
| **SF-36p**                                                   | **SF-36m**                                                                 |
| Multivariable models corrected                                | Multivariable models corrected |
| \( R^2 = 28\%^{***} \)                                       | \( R^2 = 31\%^{***} \)                                                         |
| Variables                                                   | 40–59 years       | 50–60 years       | 40–59 years       | 60–80 years       |
| TT, nmol/L                                                  | 0.21             | 0.23*             | 0.29*             |                  |
| cFT, nmol/L                                                 | 0.24*            | 0.31              | 0.17              | 0.17             |
| DHEAS, ng/ml (In)                                           | 0.16             | 0.32*             | 0.18*             | 0.34             |
| IGF-1, ng/ml                                                | 0.22             | 0.32*             | 0.34              | 0.136            |
| HbA1c, %                                                    | \(-0.20^*\)      | \(-0.21^*\)       | \(-0.34\)         | \(-0.34\)        |
| Obesity, yes vs. no                                        | 0.23*            | 0.23*             | 0.34              | 0.23*            |
| MetS, yes vs. no                                            | –                | 0.34              | 0.21*             | –                |

Note. Data are presented as standardized regression coefficients \( \beta \) (both in univariable and multivariable models). All variables shown to be significant determinants of the means of SF-36_m and SF-36_p in the univariable models \( (p < .05) \) were included in the multivariable models.

ln = natural logarithm; PD = prediabetes.

\(^* p < .05. \ ^{**} p < .01; \ ^{***} p < .001.\)
disordered glucose metabolism. It was reported that weight gain or development of T2DM is a major driver of the age-related decline in TT levels (Travis, Araujo, Kupelian, O’Donnell, & McKinlay, 2007). The latest research indicates that nonalcoholic fatty liver disease, often observed in men with obesity and T2DM, may be associated with testicular damage (germinal epithelial loss), and perhaps with an impairment of androgen synthesis (López-Lemus et al., 2018).

HRQoL is considered as a patient-assessed or patient-centered outcome that relates to the individual’s health perceptions, well-being, and functioning, and reflects a personal sense of physical and mental health along with the ability to react to factors in the physical and social environments (Fortin et al., 2004; Snoek, 2000). Several studies reported lower HRQoL in people diagnosed with T2DM. Furthermore, evidence suggests that the level of HRQoL is dependent on the presence of comorbidities and the severity of complications (Glasgow, Ruggiero, Eakin, Dryfoos, & Chobanian, 1997; United Kingdom Prospective Diabetes Study Group, 1999). These vascular complications are associated with high risk of coronary heart disease, stroke and peripheral arterial disease, and may lead to a significant decrease in HRQoL. However, complications as a result of T2DM are not limited just to cardiovascular consequences but can also encompass psychological, sexual, and hormonal states thereby resulting in a reduced HRQoL (Lagani, Koumakis, Chiarugi, Lakasing, & Tsamardinos, 2013). In men with T2DM, lifestyle-related behaviors including tobacco smoking, drinking alcohol, and physical activity status were associated with adherence to healthy lifestyle behavior and self-reported health but not QoL (Bishwajit, Tang, Yaya, He, & Feng, 2017). These results indicate that there are other factors beyond the lifestyle that affect QoL in patients with T2DM. So, although the negative impact of T2DM on quality of life is well-known, but knowledge of the impact of T2DM on HRQoL is still limited.

Impaired HRQoL in men with PD may be in part related to neuropathies and macrovascular disease. PD is found to be associated with both dysfunction of cardiac autonomic activity as well as increased prevalence of erectile dysfunction (ED; Wu et al., 2007; Grover et al., 2006). There is also increasing evidence demonstrating a higher frequency for the occurrence of idiopathic polyneuropathy and painful sensory neuropathy (Nebuchennykh, Loseth, Jorde, & Melilgren, 2008; Singleton, Smith, & Bromberg, 2001). PD has been associated with an increased risk for developing CVD but whether this elevated risk is due to PD itself or due to the development of T2DM remains as yet unclear (Seshasai et al., 2011).

As noted above, the prevalence of ED in men with PD is higher than in healthy peers. On the other hand, in case of PD, LOH was diagnosed in approximately 30% of the patients and only 14% of the control group (Rabijewski et al., 2015). Because ED is one of the most prominent symptom of hypogonadism, these results clearly indicate that PD may influence sexual health and HRQoL directly and anabolic hormone deficiency indirectly. In this study, as compared to the control group, the subjects with PD had significantly lower TT and cFT levels; also, elderly men with PD had lower androgen levels than middle-aged men. These observed discrepancies were significant even after adjustment for age and BMI. On the other hand, Brooke et al. (2014) reported that testosterone deficiency and severity of ED are independently associated with reduced quality of life in men with T2DM.

Literature regarding the relationship between anabolic hormones and glucose metabolism disturbances are very limited. Colao et al. (2008) demonstrated that IGF-1 levels in the low-normal range are associated with IFG in males without pituitary diseases. Kameda et al. (2005) presented that low DHEAS levels in male patients are associated with the progression of PD to T2DM. These results have suggested that DHEAS and IGF-1 also play an important role in glucose metabolism in men; however, their influence on HRQoL in patients with PD is still unknown.

Patients with T2DM are twice as likely to be depressed as compared to the healthy population (Seshasai et al., 2011). Depression among T2DM patients is associated with increased diabetic complications (Colao et al., 2008) and poor glycemic control (Kameda et al., 2005). These results indicate that in men with PD, poorer HRQoL may be partially associated with a tendency to be depressed as also with low androgen levels. The association between low TT levels and depression, loss of libido, and vigor in men is well documented (Johnson, Nachtigall, & Stern, 2013).

The applied methodological model has enabled to establish a causal link between PD, anabolic androgen levels, and HRQoL. The results of this study have demonstrated that different hormonal mechanisms are involved in the regulation of HRQoL in middle-aged and elderly patients with PD. The signs and symptoms of PD and low androgens levels might overlap but they are highly likely to have separate pathophysiologic pathways.

It should be noted that this study has been conducted under certain limitations. The anabolic androgen measurements were not repeated in a sample set; hence total and free testosterone might not accurately describe the subject’s bioavailable testosterone. It should also be noted that insulin levels were not measured and therefore the relationship between insulin and anabolic hormones was not assessed, whereas HbA1c was used as a marker of glucose metabolism disorders. In the discussed study, a
negative relationship between HbA1c and HRQoL was reported but it is not clear whether an improvement in glycemic control in patients with PD can lead to significant improvement of HRQoL. Effects of alcohol and smoking have not been included as covariates in the analysis, because originally our research aimed to focus on metabolic, clinical, and hormonal aspects in patients with PD.

It seems reasonable to diagnose hormone deficiencies in men with PD because evidence derived from clinical studies supports the use of replacement therapy in hypogonadal patients with glucose metabolism disorders although the benefit–risk ratio is uncertain in an advanced age. Testosterone replacement therapy may improve insulin sensitivity and glycemic control in men with T2DM as well as LOH and IGT (Lee et al., 2005; Krysiak, Gilowski, & Okopień, 2015; Haider, Yassin, Doros, & Saad, 2014; Jones et al., 2011), but long-term influence of testosterone in men with PD is still unknown.

Conclusions
In conclusion, PD in men is associated with decreased HRQoL in comparison with healthy subjects. It probably means that even a small degree of disturbance in glucose metabolism may cause a deterioration in the HRQoL in men. Hormonal determinants of HRQoL are different in middle-aged and elderly men with PD, but anabolic hormones may play an important role. Generally, better quality of life in men with PD is associated with higher testosterone, higher FT, higher DHEAS, and lower HbA1c.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD
Michal Rabijewski https://orcid.org/0000-0002-2049-7427

References
American Diabetes Association. (2014). Diagnosis and classification of diabetes mellitus. *Diabetes Care, 33*(Suppl 1), S62–S69. Retrieved from http://doi.org/10.2337/dc13-S062
Athyros, G. V., Ganotakis, E. S., & Mikhailidis, D. O. (2005). The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. *Current Medical Research and Opinion, 21*(8), 1157–1164.
Bergman, M. (2013). Pathophysiology of prediabetes and treatment implications for the prevention of type 2 diabetes mellitus. *Endocrine, 43*(3), 504–513.
Bishwajit, G., Tang, S., Yaya, S., He, Z., & Feng, Z. (2017). Lifestyle behaviors, subjective health, and quality of life among Chinese men living with type 2 diabetes. *American Journal of Men’s Health, 11*(2), 357–364.
Brooke, J. C., Walter, D. J., Kapoor, D., Marsh, H., Muraleedharan, V., & Jones, T. H. (2014). Testosterone deficiency and severity of erectile dysfunction are independently associated with reduced quality of life in men with type 2 diabetes. *Andrology, 2*(2), 205–211.
Centers for Disease Control and Prevention. (2014). *National diabetes statistics report: Estimates of diabetes and its burden in the United States*, Atlanta, GA: US Department of Health and Human Services.
Colao, A., Di Somma, C., Cascella, T., Pivonello, R., Vitale, G., Grasso, L. F., … Savastano, S. (2008). Relationships between serum IGF1 levels, blood pressure, and glucose tolerance: An observational, exploratory study in 404 subjects. *European Journal of Endocrinology, 159*(4), 389–397.
Corona, G., Rastrelli, G., Baler西亚, Lotti, F., Sforza, A., Monami, M., … Maggio, M. (2012). Hormonal association and sexual dysfunction in patients with impaired fasting glucose: A cross-sectional and longitudinal study. *The Journal of Sexual Medicine, 9*(6), 1669–80.
Dhindsa, S., Prabhakar, S., Sethi, M., Bandyopadhyay, A., Chaudhuri, A., & Dandona, P. (2004). Frequent occurrence of hypogonadotrophic hypogonadism in type 2 diabetes. *The Journal of Clinical Endocrinology & Metabolism, 89*(11), 5462–5468.
Fillo, J., Leveikova, M., Onodrusova, M., Breza, J., & Labas, P. (2017). Importance of different grades of abdominal obesity on testosterone level, erectile dysfunction, and clinical coincidence. *American Journal of Men’s Health, 11*(2), 240–245.
Fortin, M., Lapointe, L., Hudon, C., Vanasse, A., Ntetu, A., & Maltais, D. (2004). Multimorbidity and quality of life in primary care: A systematic review. *Health and Quality of Life Outcomes, 2*, 51. Retrieved from http://doi.org/10.1186/1477-7525-2-51
Gerstein, H. C., Santaguida, P., Raina, P., Morrison, K. M, Balion, C, Hunt, D, … Bookle, L. (2007). Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: A systematic overview and meta-analysis of prospective studies. *Diabetes Research and Clinical Practice, 78*(3), 305–312.
Glasgow, R. E., Ruggiero, L., Eakin, E. G., Dryfoos, J., & Chobanian, L. (1997). Quality of life and associated characteristics in a large national sample of adults with diabetes. *Diabetes Care, 20*(4), 562–567.
Godijn, P. P., Bilò, H. J., Feskens, E. J., Groenier, K. H., van der Zee, K. I., & Meyboom-de Jong, B. (1999). Longitudinal study on glycaemic control and quality of life in patients with Type 2 diabetes mellitus referred for intensified control. *Diabetic Medicine, 16*(1), 23–30.
Goldney, R. D., Phillips, P. J., Fisher, L. J., & Wilson, D. H. (2004). Diabetes, depression and quality of life. *Diabetes Care, 7*(5), 1066–1670.
Grossmann, M. (2014). Testosterone and glucose metabolism in men: Current concepts and controversies. *The Journal of Endocrinology, 27*(220)(3), R37–R55.

Grover, S. A., Lowenstein, I., Kaoutsche, M., Marchand, S., Coupar, E., DeCarolis, E., … Defoy, I. (2006). The prevalence of erectile dysfunction in the primary care setting: Importance of risk factors for diabetes and vascular disease. *Archives of Internal Medicine, 166*(2), 213–219.

Haider, A., Yassin, A., Doros, G., & Saad, F. (2014). Effects of long-term testosterone therapy on patients with “diabetes”: Results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetes. *International Journal of Endocrinology, 2014*, 1–15. Retrieved from http://doi.org/10.1155/2014/683515

Haywood, K. L., Garratt, A. M., & Fitzpatrick, R. (2005). Quality of life in older people: A structured review of generic self-assessed health instruments. *Quality of Life Research, 14*(7), 1651–1668.

Ho, C. H., Yu, H. J., Wang, C. Y., Jaw, F. S., Hsieh, J. T., Liao, W. C., …Liu, S. P. (2013). Prediabetes is associated with an increased risk of testosterone deficiency, independent of obesity and metabolic syndrome. *PLOS ONE, 8*(9), e74173.

International Diabetes Federation. (2017). *IDF diabetes atlas* (8th ed.). Brussels, Belgium: International Diabetes Federation. Retrieved from http://www.diabetesatlas.org; ISBN: 978-2-930229-87-4

Johnson, J. M., Nachtigall, L. B., & Stern, T. A. (2013). The effect of testosterone levels on mood in men: A review. *Psychosomatics, 54*(6), 509–514.

Jones, T. H., Arver, S., Behre, H. M., Buvat, J., Meuleman, E., Moncada, I., … Channer, K. S. (2011). Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). *Diabetes Care, 34*(4), 828–837.

Kameda, W., Daimon, M., Oizumi, T., Jimbu, Y., Kimura, M., Hirata, A., … Kato, T. (2005). Association of decrease in serum dehydroepiandrosterone sulfate levels with the progression to type 2 diabetes in men of a Japanese population: The Funagata study. *Metabolism, 54*(5), 669–676.

Kapoor, D., Aldred, H., Clark, S., Channer, K. S., & Jones, T. H. (2007). Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: Correlations with bioavailable testosterone and visceral adiposity. *Diabetes Care, 30*(4), 911–917.

Krysiak, R., Gilowski, W., & Okopien, B. (2015). The effect of metformin and metformin-testosterone combination on cardiometabolic risk factors in men with late-onset hypogonadism and impaired glucose tolerance. *Experimental and Clinical Endocrinology & Diabetes, 123*(10), 608–613.

Lagani, V., Koumakis, L., Chiarugi, F., Lakasing, E., & Tsamardinos, I. (2013). A systematic review of predictive risk models for diabetes complications based on large scale clinical studies. *Journal of Diabetes and its Complications, 27*(4), 407–413.

Lee, C. H., Kuo, S. W., Hung, Y. J., Hsieh, C. H., He, C. T., Yang, T. C., … Pei, D. (2005). The effect of testosterone supplement on insulin sensitivity, glucose effectiveness, and acute insulin response after glucose load in male type 2 diabetics. *Endocrine Research, 31*(2), 139–148.

López-Lemus, U. A., Garza-Guajardo, R., Barboza-Quintana, O., Rodríguez-Hernandez, A., García-Rivera, A., Madrigal-Pérez, V. M., …Delgado-Enciso, I. (2018). Association between nonalcoholic fatty liver disease and severe male reproductive organ impairment (germinal epithelial loss): Study on a mouse model and on human patients. *American Journal of Men’s Health, 12*(3), 639–648.

Maggio, M., Lauretani, F., Ceda, G. P., Bandinelli, S., Ling, S. M., Metter, E. J., … Ferrucci, L. (2007). Relationship between low levels of anabolic hormones and 6-year mortality in older men: The aging in the Chianti Area (InCHIANTI) study. *Archives of Internal Medicine, 167*(20), 2249–2254.

Nebuchennykh, M., Loseth, S., Jorde, R., & Mellgren, S. I. (2008). Idiopathic polyneuropathy and impaired glucose metabolism in a Norwegian patient series. *European Journal of Neurology, 15*(8), 810–816.

Rabijewski, M., Papierska, L., & Piątkiewicz, P. (2015). Late-onset hypogonadism among old and middle-aged males with prediabetes in Polish population. *Aging Male, 18*(1), 16–21.

Rubin, R. R., & Peyrot, M. (1999). Quality of life and diabetes. *Diabetes/Metabolism Research and Reviews, 15*(3), 205–218.

Schianca, G. P., Fra, G. P., Brustia, F., Bellan, M., Pirovano, A., Gualerzi, A., … Pirisi, M. (2017). Testosterone plasma concentration is associated with insulin resistance in male hypertensive patients. *Experimental and Clinical Endocrinology & Diabetes, 125*(3), 171–175.

Seshasai, S. R., Kaptoge, S., Thompson, A., Di Angelantonio, E., Gao, P., Sarwar, N., … Danesh, J. (2011). Diabetes mellitus, fasting glucose, and risk of cause-specific death. *The New England Journal of Medicine, 364*(9), 829–841.

Singh, R., Artaza, J. N., Taylor, W. E., Gonzalez-Cadavid, N. F., & Bhasin, S. (2003). Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H10T1/2 pluripotent cells through an androgen receptor-mediated pathway. *Endocrinology, 144*, 5081–5088.

Singleton, J. R., Smith, A. G., & Bromberg, M. B. (2001). Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. *Diabetes Care, 24*(8), 1448–1453.

Snoek, F. J. (2000). Quality of life: A closer look at measuring patients’ well-being. *Diabetes Spectrum, 13*(2), 24–28.

Travison, T. G., Araujo, A. B., Kupelian, V., O’Donell, A. B., & McKinlay, J. B. (2007). He relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. *The Journal of Clinical Endocrinology & Metabolism, 92*, 549–555.

United Kingdom Prospective Diabetes Study Group (UKPDS). (1999). Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. Prospective Diabetes Study Group. *Diabetes Care, 22*(7), 1125–1136.

Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999). A critical evaluation of simple methods for the estimation of free testosterone in serum. *The Journal of Clinical Endocrinology & Metabolism, 84*(10), 3666–7362.
Wang, C., Jackson, G., Jones, T. H., Matsumoto, A. M., Nehra, A., Perelman, M. A., … Cunningham, G. (2011). Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease in men with type 2 diabetes. *Diabetes Care, 34*(7), 1660–1675.

Ware, J., Snow, K., Kosinski, M., & Gandek, B. (1993). *SF-36 health survey. Manual and interpretation guide.* Boston, MA: New England Medical Center, The Health Institute.

Wu, J. S., Yang, Y. C., Lin, T. S., Huang, Y. H., Chen, J. J., Lu, F. H., … Chang, C. J. (2007). Epidemiological evidence of altered cardiac autonomic function in subjects with impaired glucose tolerance but not isolated impaired fasting glucose. *The Journal of Clinical Endocrinology & Metabolism, 92*(5), 3885–3889.